RespireRx Pharmaceuticals Inc (fka RSPI)

[enemem]

The most plausible course of action IMO is to focus on the patient population already chronically using opioids to manage pain. This patient population has big problems with SA, and because of the sedative effect of the opioids, probably will fall asleep anyway.

If corx could sign a deal to develop an opioid-ampakine combo for pain management, which dramatically reduces morbidity / mortality due to SA and/or RD, they'd have a very nice payday.